Leblond Pierre, Geoerger Birgit
Centre Oscar-Lambret, unité d'oncologie pédiatrique, 3, rue Frédéric-Combemale, 59020 Lille Cedex, France.
Bull Cancer. 2011 May;98(5):527-39. doi: 10.1684/bdc.2011.1358.
Progresses performed in pediatric oncology during the last 30 years allowed to obtain about 70 to 80% healing rates. These progresses are the result of the optimization of the cytotoxic chemotherapies protocols used at standard and high doses, as well as the improvement of the local treatment. Most of the new anticancer treatments currently in developmental stage are based on targeted therapies, acting against numerous tumor cell abnormalities, like growth factors et their receptors, cell proliferation-inducing factors, molecules involved in DNA repair, cell death inducers, tumor invasion and angiogenesis. They are widely used in adult patients since 10 years and they are being more and more employed in children with cancer. The aim of this article is to review the main indications of these new targeted drugs in pediatric oncology and the new developments of these drugs.
过去30年里，儿科肿瘤学取得的进展使治愈率达到了约70%至80%。这些进展是标准剂量和高剂量细胞毒性化疗方案优化以及局部治疗改善的结果。目前处于研发阶段的大多数新型抗癌治疗方法都基于靶向疗法，作用于众多肿瘤细胞异常情况，如生长因子及其受体、细胞增殖诱导因子、参与DNA修复的分子、细胞死亡诱导剂、肿瘤侵袭和血管生成。这些药物自10年前起在成年患者中广泛使用，并且越来越多地应用于患癌儿童。本文旨在综述这些新型靶向药物在儿科肿瘤学中的主要适应证以及这些药物的新进展。
